Back to Lung Cancer
NCT01737502
NCT01737502
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with lung cancer (specifically squamous cell, a type called RAS-mutated adenocarcinoma, or small cell lung cancer), confirmed by a tissue or cell sample test
- You have already received at least one round of chemotherapy that included a platinum-based drug combination, and there are no other standard treatment options available to you
- If you had previous radiation therapy, you have recovered from its side effects before joining (hair loss is the exception — that is acceptable)
- Your blood counts are at acceptable levels: enough white blood cells, platelets, and red blood cells (confirm specific numbers with trial site)
- Your liver function tests are within acceptable ranges (confirm with trial site)
- You are reasonably active and able to care for yourself to a basic degree (rated 0, 1, or 2 on a standard activity scale)
- If you are a woman who could become pregnant, you have had a negative pregnancy test within 7 days before registering
- You are able to understand and agree to the study terms
- You are expected to live at least 12 weeks or more
- You are willing to return to the enrolling Mayo Clinic location for follow-up visits
- You are willing to provide tissue samples for research purposes as part of the study
Who may not be able to join:
- You are pregnant or currently breastfeeding
- You are a man or woman capable of having children but are unwilling to use adequate birth control during the study
- You have brain or spinal cord involvement from your cancer that is causing symptoms, has not been treated, or is not well controlled; however, if your brain involvement has been treated and is stable without symptoms or need for steroids, you may still be eligible (confirm with trial site)
- You are HIV-positive and currently taking combination anti-retroviral medication
- You are unwilling or unable to follow the study requirements
- You previously received radiation to a large portion (25% or more) of your bone marrow
- You had major surgery or a significant injury within the past 4 weeks, or minor surgery within the past 2 weeks (placement of a port or IV access device does not count as surgery here)
- You have certain serious or poorly controlled health conditions, including: high blood pressure that is difficult to control or a history of not following blood pressure treatment; chest pain from heart disease; heart failure within the last 3 months (unless your heart is pumping adequately); a heart attack within the last 6 months; an irregular heartbeat; poorly controlled diabetes; serious lung scarring or inflammation; coughing up blood recently (though if this has been treated and resolved for more than 14 days, you may still be considered — confirm with trial site); significantly high triglyceride or cholesterol levels; or any other illness that the study doctor feels would make it unsafe for you to participate
- You are currently taking St. John's Wort (a herbal supplement), as it affects how the body processes certain medications
- You have another active cancer, except for certain limited exceptions such as non-melanoma skin cancer, localized prostate cancer, or early-stage cervical changes; and you must not be receiving other cancer-fighting drugs (certain hormone treatments may be allowed at the doctor's discretion — confirm with trial site)
- You are taking certain medications that strongly affect how the body breaks down drugs through a specific liver pathway, and you are unable to stop taking them (confirm specific medications with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 2
Sponsor
Mayo Clinic
Registry
clinicaltrials_gov
Start date
14 May 2014
Est. completion
24 April 2023
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Number of Phase 1 Patients Experiencing a DLT; Number Phase 1 Patients Experiencing a Grade 3+ AE; Progression-free Survival Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.